Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2xTJVKUUN3ME2wMlA3OSEQvF2= NYT4VIliW0GQR1XS
ALL-PO NIS4W|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGWzUmFKSzVyPUCuNFY{PTVizszN MUHTRW5ITVJ?
697 M4O0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\sOmlEPTB;MD6wPVk4PiEQvF2= Mn;aV2FPT0WU
NCI-H748 NFXPUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHvTWM2OD1yLkGwN|M1KM7:TR?= M3XodHNCVkeHUh?=
NKM-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTROnNoUUN3ME2wMlExQTF{IN88US=> NGfhUVJUSU6JRWK=
ES1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLQdGFQUUN3ME2wMlEyOjV3IN88US=> M4nm[nNCVkeHUh?=
NCI-H1963 NI\LXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzGXWFtUUN3ME2wMlEyPTd7IN88US=> NXj6U2pCW0GQR1XS
NCI-H1417 M1nxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMUK5O|Qh|ryP MXXTRW5ITVJ?
NEC8 M2DTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Hmd2lEPTB;MD6xN|UzPyEQvF2= MmDHV2FPT0WU
CRO-AP2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TIN2lEPTB;MD6xOlg5QSEQvF2= NH7kcZpUSU6JRWK=
A3-KAW MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMUe2Nlch|ryP NFPGRnJUSU6JRWK=
SF539 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3pPWlKSzVyPUCuNVk2QTNizszN MVXTRW5ITVJ?
NOS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LncGlEPTB;MD6xPVYyQSEQvF2= MX;TRW5ITVJ?
NTERA-S-cl-D1 NEfPeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfOSWxKSzVyPUCuNlAyOTNizszN NUfVUVZoW0GQR1XS
COR-L88 NWCySXVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6zWHBVUUN3ME2wMlIzQTV7IN88US=> Mo\4V2FPT0WU
EM-2 NG[yWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMkSwO|kh|ryP M13vd3NCVkeHUh?=
KARPAS-45 NF3DeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDJeG9YUUN3ME2wMlI4QDN|IN88US=> NI\OZnpUSU6JRWK=
DSH1 NIrVO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXThbYdFUUN3ME2wMlI5PzB6IN88US=> MX3TRW5ITVJ?
HT-144 M1vIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwM{CyOVYh|ryP NVLmfWFoW0GQR1XS
ATN-1 M3eyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr5fYJUUUN3ME2wMlMxPTd4IN88US=> M1zvPXNCVkeHUh?=
HEL NX;mVlltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nFSGlEPTB;MD6zNVM1QCEQvF2= Mnr2V2FPT0WU
NB12 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHONYF6UUN3ME2wMlMyPzV4IN88US=> M3LHOXNCVkeHUh?=
LU-139 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwM{O1NUDPxE1? MnnTV2FPT0WU
J-RT3-T3-5 NUPC[lBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwM{O3NVYh|ryP NX;ibmNWW0GQR1XS
MOLT-13 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv1bIlKSzVyPUCuN|M5OSEQvF2= MXnTRW5ITVJ?
SR M1j2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnKRYpNUUN3ME2wMlM1OjZzIN88US=> MnH1V2FPT0WU
CMK M1G2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe3[WpKSzVyPUCuN|U4OjdizszN MnTlV2FPT0WU
ES8 M1:xV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;u[FBqUUN3ME2wMlM3ODJ{IN88US=> MoLsV2FPT0WU
LB647-SCLC NVrTdWJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD2TWM2OD1yLkO2O|Mh|ryP NEHRTYtUSU6JRWK=
TE-8 M2CxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PyN2lEPTB;MD6zOlk{PSEQvF2= MXjTRW5ITVJ?
BV-173 MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3OTWM2OD1yLkO3NVIyKM7:TR?= MXfTRW5ITVJ?
DEL MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LDXGlEPTB;MD6zO|Q5PyEQvF2= MoPXV2FPT0WU
ARH-77 NWXSV3l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwM{ixPVMh|ryP M3HqR3NCVkeHUh?=
NCCIT M33DVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7POndLUUN3ME2wMlM5PjR7IN88US=> MVHTRW5ITVJ?
RPMI-8402 NXvRU5VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHnTWM2OD1yLkO4O|AyKM7:TR?= NF\WPY1USU6JRWK=
MONO-MAC-6 NXHRbnc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwM{i3O|Yh|ryP MX;TRW5ITVJ?
SK-MM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nhemlEPTB;MD6zPVg3QCEQvF2= Mn\PV2FPT0WU
CHP-126 NIXUU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHzWnpnUUN3ME2wMlQxOjNzIN88US=> NIXxRnZUSU6JRWK=
A101D MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPuTWM2OD1yLkSwN{DPxE1? M3fxWXNCVkeHUh?=
SCH MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;xTWM2OD1yLkSwN|QzKM7:TR?= MonBV2FPT0WU
NMC-G1 NVHYV2s4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPsfW1QUUN3ME2wMlQxOzZ5IN88US=> NHTyU|NUSU6JRWK=
NCI-H209 M{[wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwNEC2NVMh|ryP NGn1ZohUSU6JRWK=
MOLT-16 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT2ZY12UUN3ME2wMlQyODF5IN88US=> NH7lVG1USU6JRWK=
RPMI-6666 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rnRWlEPTB;MD60NVEzKM7:TR?= M{Xl[XNCVkeHUh?=
OPM-2 NXPRS2xmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXMOmhKSzVyPUCuOFE2OTNizszN NGrWb21USU6JRWK=
MRK-nu-1 NEDF[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwNEOxOVMh|ryP Mle0V2FPT0WU
BC-1 NGfmT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNEO0NFMh|ryP NIn3PI5USU6JRWK=
MHH-NB-11 NV\RdHN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP1R2NKSzVyPUCuOFM1PTNizszN MUnTRW5ITVJ?
Ramos-2G6-4C10 NHfyeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n1V2lEPTB;MD60N|g6PyEQvF2= MnPYV2FPT0WU
LS-513 M1P3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPkTWM2OD1yLkS0OVAyKM7:TR?= NXLJXJB3W0GQR1XS
K5 M2n1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16ycWlEPTB;MD60O|AzPSEQvF2= NXXCfnBqW0GQR1XS
HOP-62 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT3OYtjUUN3ME2wMlQ5OzV6IN88US=> M{O2[3NCVkeHUh?=
NCI-H187 Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHWU4hKSzVyPUCuOFkzOjdizszN MnThV2FPT0WU
BE-13 MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwNEm2OlEh|ryP NWjJboV3W0GQR1XS
HC-1 NUj5ZYN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nQfmlEPTB;MD61NFQ4OyEQvF2= NWizTIN[W0GQR1XS
ACN NIXtT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\XOHFwUUN3ME2wMlUyODJ6IN88US=> M3rG[nNCVkeHUh?=
HCC1599 NI\HbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHtTWM2OD1yLkWxOVch|ryP NVvKbot[W0GQR1XS
MV-4-11 NYraem5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwNUOwOFEh|ryP M1jyW3NCVkeHUh?=
LC-2-ad MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwNUO2OlMh|ryP MYXTRW5ITVJ?
HL-60 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTOZpJrUUN3ME2wMlU1OjZzIN88US=> M4LPfHNCVkeHUh?=
NB17 M2jZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXGTYJKSzVyPUCuOVQ{QCEQvF2= MoHMV2FPT0WU
TE-1 NXH0THJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jqSmlEPTB;MD61OVMxPiEQvF2= M4K5V3NCVkeHUh?=
NCI-H524 M{m0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f5PGlEPTB;MD61OVQxOSEQvF2= MYXTRW5ITVJ?
MZ7-mel M2DTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DafGlEPTB;MD61OlExPSEQvF2= MnXSV2FPT0WU
L-363 NHnlbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ufJlDUUN3ME2wMlU3PjV5IN88US=> MofVV2FPT0WU
BL-41 NYnucph[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\PU5dKSzVyPUCuOVY5QDlizszN NV3qPHJwW0GQR1XS
LU-134-A NFqwZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn6fWY4UUN3ME2wMlU4ODd|IN88US=> NYXvc5hWW0GQR1XS
SIG-M5 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7hNoh{UUN3ME2wMlU4QDR6IN88US=> M2LQdHNCVkeHUh?=
ONS-76 M1[3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfrNGxIUUN3ME2wMlU5OjR{IN88US=> MVLTRW5ITVJ?
KARPAS-299 NYnZT|VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DybGlEPTB;MD61PFUxPCEQvF2= NXG0NllSW0GQR1XS
DU-4475 M{TUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HGe2lEPTB;MD61PFcxOyEQvF2= M{HlZXNCVkeHUh?=
NB69 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi3PVI6UUN3ME2wMlU6QDJ3IN88US=> NUjKW|E2W0GQR1XS
MHH-PREB-1 M4CxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH62PXRKSzVyPUCuOlA4OTlizszN MYXTRW5ITVJ?
LU-165 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHwcFhKSzVyPUCuOlE5OTJizszN MXXTRW5ITVJ?
LOUCY M3X3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTFfpNxUUN3ME2wMlY{OzZ2IN88US=> NXOzO|A3W0GQR1XS
NCI-H526 MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLncpdMUUN3ME2wMlY{PTRzIN88US=> NYXWbVYzW0GQR1XS
KE-37 M3;ERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHLVJFTUUN3ME2wMlY1Ojd4IN88US=> NWC5[G9UW0GQR1XS
NALM-6 M{\OXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvyVWNKSzVyPUCuOlQ5PiEQvF2= NVnUSlBPW0GQR1XS
CW-2 NVv3U2NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W1[2lEPTB;MD62OVc6PCEQvF2= M2f3XHNCVkeHUh?=
SU-DHL-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljVTWM2OD1yLk[1PVQ4KM7:TR?= NGrCd2FUSU6JRWK=
NB13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jjXGlEPTB;MD62OlgyPyEQvF2= NYfXfXhpW0GQR1XS
QIMR-WIL MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXiTWM2OD1yLk[4N|Q{KM7:TR?= MVHTRW5ITVJ?
ECC12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{eyXWlEPTB;MD63NFA5PiEQvF2= NYfsdJVXW0GQR1XS
KALS-1 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwN{C0PVIh|ryP MWjTRW5ITVJ?
COR-L279 NFriVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILXTJdKSzVyPUCuO|A6QTZizszN MnvFV2FPT0WU
NB14 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v6SGlEPTB;MD63NlYyPyEQvF2= NF\vdFlUSU6JRWK=
CCRF-CEM NGH3N5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwN{S2OlEh|ryP MlfzV2FPT0WU
SW954 M1HpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnkUFZTUUN3ME2wMlc2QTl7IN88US=> MkjCV2FPT0WU
IST-SL1 M2fTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwN{ezOFgh|ryP MVrTRW5ITVJ?
LAMA-84 MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XJUmlEPTB;MD63O|U3PyEQvF2= NGjMPG5USU6JRWK=
Daudi MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV24WYxOUUN3ME2wMlc4PjhzIN88US=> NYXPZWpTW0GQR1XS
BC-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XIPWlEPTB;MD63PFMxQCEQvF2= NXz0bVZ3W0GQR1XS
HCC2998 M{nGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwN{izOkDPxE1? MYrTRW5ITVJ?
NCI-H69 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPtRWx5UUN3ME2wMlgxOTR5IN88US=> NVywR2M6W0GQR1XS
CPC-N MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi4TWM2OD1yLkiwOVI1KM7:TR?= MWnTRW5ITVJ?
NOMO-1 NYXvV4UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGqxcXdKSzVyPUCuPFExQDRizszN MUPTRW5ITVJ?
CESS MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwOEGxPVch|ryP M3LrfHNCVkeHUh?=
LC4-1 MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC0c3BKSzVyPUCuPFQxODdizszN MYXTRW5ITVJ?
BL-70 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LnSWlEPTB;MD64OVcxOiEQvF2= NHTYU21USU6JRWK=
ES4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln4TWM2OD1yLki1PFY5KM7:TR?= NITKWpZUSU6JRWK=
HCE-T MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vLXmlEPTB;MD64O|E4OSEQvF2= NH23bYJUSU6JRWK=
JAR NXnHZoxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TjU2lEPTB;MD64O|gzPyEQvF2= NX\4cWdRW0GQR1XS
ST486 NH;1c5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjidGxzUUN3ME2wMlg4QTF5IN88US=> MWHTRW5ITVJ?
KS-1 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWryd5A5UUN3ME2wMlg5ODl4IN88US=> M4LyeXNCVkeHUh?=
GDM-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwOEi2PFch|ryP MlXNV2FPT0WU
EHEB M4PqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj3fVlKSzVyPUCuPVI2QDVizszN MoSxV2FPT0WU
LB2518-MEL M3HCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF70SXJKSzVyPUCuPVMzQDRizszN NFfWWYpUSU6JRWK=
GOTO NFP1PJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP2TWM2OD1yLkm1NFc3KM7:TR?= MmnKV2FPT0WU
LXF-289 NUX3R3lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwOUW5NFEh|ryP MmXrV2FPT0WU
ES6 NXrze4JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwOU[0N|ch|ryP MWDTRW5ITVJ?
OS-RC-2 M1jwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvqTWM2OD1yLkm2PFMh|ryP MUHTRW5ITVJ?
DMS-153 NGPpPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nFN2lEPTB;MD65O|Q3QSEQvF2= M2rSOXNCVkeHUh?=
SK-PN-DW NGLze2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwOUe4N|Eh|ryP MYXTRW5ITVJ?
HH NIq0WGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jtZWlEPTB;MD65PFk2QSEQvF2= NYLRPIlXW0GQR1XS
SH-4 M3nEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTFwMEK0NUDPxE1? M17JcnNCVkeHUh?=
MOLT-4 NV\xT2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWyOIQ2UUN3ME2xMlA{PDV2IN88US=> MoO1V2FPT0WU
TGW NHnmbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwMEe2O|Uh|ryP MU\TRW5ITVJ?
L-540 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HT[mlEPTB;MT6xNFYxPCEQvF2= M3TyZnNCVkeHUh?=
PF-382 M4flXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13pUmlEPTB;MT6xNVUyOyEQvF2= MlTyV2FPT0WU
LC-1F MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3RXox{UUN3ME2xMlEzODB5IN88US=> M3vRTXNCVkeHUh?=
OVCAR-4 NFK4fGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXLRmtKSzVyPUGuNVMyPjVizszN MYHTRW5ITVJ?
A4-Fuk Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET5N2lKSzVyPUGuNVU{PjRizszN NGfoUIhUSU6JRWK=
HCC2218 M{HVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DwS2lEPTB;MT6xOlY1OSEQvF2= M4fy[XNCVkeHUh?=
HAL-01 NYi2[lhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITRNY5KSzVyPUGuNVY6PDNizszN MXrTRW5ITVJ?
IST-MEL1 NITlNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwMUe2OVkh|ryP MnLUV2FPT0WU
NCI-H719 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vhe2lEPTB;MT6xO|g6QCEQvF2= Mme1V2FPT0WU
EVSA-T MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLmWWU4UUN3ME2xMlE5OTF2IN88US=> MV;TRW5ITVJ?
SK-NEP-1 NUWzcolqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jYXGlEPTB;MT6yNFI3PiEQvF2= NXnxSYpZW0GQR1XS
OCUB-M MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwMkG0PFkh|ryP NH\tTJFUSU6JRWK=
MEG-01 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDGTWM2OD1zLkKyNVE5KM7:TR?= M13HNXNCVkeHUh?=
no-10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17LS2lEPTB;MT6yN|EyOiEQvF2= M3r2WXNCVkeHUh?=
MHH-CALL-2 M4XoRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwMkS3NlEh|ryP NGXBdo5USU6JRWK=
SK-N-DZ MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFwMkS3O|Yh|ryP NXLnN5VGW0GQR1XS
SCLC-21H M{Twbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\rOWlEPTB;MT6yOlQ4QCEQvF2= M{PCUHNCVkeHUh?=
CTV-1 NVzJUWtWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHVUHExUUN3ME2xMlI4PDJ3IN88US=> MYPTRW5ITVJ?
NB1 NHPOdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnZbJRXUUN3ME2xMlI4PzN{IN88US=> M2[2ZXNCVkeHUh?=
NCI-H64 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfMW4lKSzVyPUGuNlg1PjJizszN M{T6OHNCVkeHUh?=
MDA-MB-134-VI NGX6dGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XsVmlEPTB;MT6yPFU4PyEQvF2= NIfHcGlUSU6JRWK=
LB2241-RCC M3i3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLLTWM2OD1zLkK4OlY{KM7:TR?= M3jE[HNCVkeHUh?=
8-MG-BA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7rTWM2OD1zLkK4PFY3KM7:TR?= MUXTRW5ITVJ?
LP-1 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnTOnUxUUN3ME2xMlI6QTR5IN88US=> NXXzcpdZW0GQR1XS
LS-411N M3THfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi1TWM2OD1zLkOwPVk5KM7:TR?= M4DOSXNCVkeHUh?=
CAL-148 M1;yN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTkTWM2OD1zLkOyOVQzKM7:TR?= MUXTRW5ITVJ?
NCI-H2171 MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwM{S1NFIh|ryP NHHWb2VUSU6JRWK=
JiyoyeP-2003 M2\MXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX6TWM2OD1zLkO1N|kh|ryP NILyTmNUSU6JRWK=
NCI-H2107 NF;ZcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvsT4N6UUN3ME2xMlM2QDh|IN88US=> MojCV2FPT0WU
BB30-HNC NVfrfokyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjOWZlKSzVyPUGuN|g6PzhizszN M4DUPHNCVkeHUh?=
K-562 M4f6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLqTWM2OD1zLkO5NlE6KM7:TR?= M1XvUXNCVkeHUh?=
PSN1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwNEKyPFch|ryP NYnaOYV1W0GQR1XS
HCC2157 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwNEK2PVEh|ryP M4fXT3NCVkeHUh?=
SBC-1 NULWe4JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzONHpKSzVyPUGuOFI4PDFizszN M2[3TXNCVkeHUh?=
MC116 M2[3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\ESmh3UUN3ME2xMlQ{PjF3IN88US=> NHK3Vm1USU6JRWK=
KARPAS-422 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\JTWlEPTB;MT60OVM2QCEQvF2= M2fXPXNCVkeHUh?=
LB996-RCC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;rTWM2OD1zLkS3NVA{KM7:TR?= MXzTRW5ITVJ?
MSTO-211H M3qyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P3ZWlEPTB;MT60O|k5PyEQvF2= NH7ncFlUSU6JRWK=
BT-474 NVrqbHhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwNUG3OlQh|ryP NWn6WlIxW0GQR1XS
A388 M1TQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\PTWM2OD1zLkWxPVQ2KM7:TR?= NU\BTHZFW0GQR1XS
SJSA-1 M3Pjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4SxTmlEPTB;MT61NlI3KM7:TR?= NHKwUmFUSU6JRWK=
COLO-829 NGGzeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e5cmlEPTB;MT61N|U3PCEQvF2= NEPNN|FUSU6JRWK=
KM-H2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknQTWM2OD1zLkW2Olch|ryP MYHTRW5ITVJ?
GR-ST NVnzTVF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf3VlZFUUN3ME2xMlU3QDJizszN MnP1V2FPT0WU
RPMI-8866 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\2SVBKSzVyPUGuOlAyPDRizszN NVvQTWhjW0GQR1XS
KG-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HLN2lEPTB;MT62NVkxOSEQvF2= MXfTRW5ITVJ?
NCI-H82 NWm2[2lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwNkO0NFYh|ryP NXXFRmpMW0GQR1XS
LB1047-RCC NW\GUo1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\VfWlEPTB;MT62N|Q2QSEQvF2= M{HpOHNCVkeHUh?=
KM12 NWqzbot3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XHXGlEPTB;MT62OFch|ryP MWrTRW5ITVJ?
NB5 M{Lucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zxN2lEPTB;MT62OVY4PyEQvF2= MYHTRW5ITVJ?
HDLM-2 NIjFTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSyOIxKSzVyPUGuOlgzQDFizszN M1vaSXNCVkeHUh?=
KU812 NEi5V4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TKV2lEPTB;MT62PVYxPSEQvF2= Mlr6V2FPT0WU
DB MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\wTWM2OD1zLkewN|U{KM7:TR?= NXLJbGg1W0GQR1XS
HD-MY-Z M2e1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jwTGlEPTB;MT63OVI{PCEQvF2= MYLTRW5ITVJ?
KURAMOCHI NVfYS|BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfiOVlVUUN3ME2xMlc4OjB5IN88US=> NXXDbYVWW0GQR1XS
ETK-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwN{i4O|kh|ryP NEmwU2RUSU6JRWK=
SK-UT-1 M4rYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwN{mzPFgh|ryP NIKyVoZUSU6JRWK=
HUTU-80 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXEXoxMUUN3ME2xMlc6PTB6IN88US=> MoC4V2FPT0WU
ES7 M{j3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn4NmR1UUN3ME2xMlgxOzB{IN88US=> NGfFZ4pUSU6JRWK=
SW872 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELHfFlKSzVyPUGuPFE{QTVizszN MUXTRW5ITVJ?
TK10 NEDxVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TMUGlEPTB;MT64N|ExQCEQvF2= NE[2[3VUSU6JRWK=
LB831-BLC NV\MPWZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwOEO1OlMh|ryP MVrTRW5ITVJ?
TE-9 MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn4N2lKSzVyPUGuPFQ1OjJizszN MVXTRW5ITVJ?
MLMA NWPxc3kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvpbmpKSzVyPUGuPFgzOzRizszN M2PyRXNCVkeHUh?=
D-542MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHZT|BzUUN3ME2xMlg6Ozd|IN88US=> NUXTO3M{W0GQR1XS
EW-16 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGftXmJKSzVyPUGuPVI4OiEQvF2= M2\zV3NCVkeHUh?=
LOXIMVI MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK1TWM2OD1zLkmzNlgh|ryP Mlr5V2FPT0WU
GB-1 NHrYOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\aPFhpUUN3ME2xMlk{QDZ4IN88US=> Mme1V2FPT0WU
IST-SL2 NXHPcVZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJwMECyOlIh|ryP MXzTRW5ITVJ?
LAN-6 NYnDU|lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvkblgyUUN3ME2yMlAyQTZ4IN88US=> M1XZU3NCVkeHUh?=
NCI-H510A NEDsUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;2NYJKSzVyPUKuNFQ2ODJizszN MYrTRW5ITVJ?
NCI-H1092 M3XXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjxTWM2OD1{LkC1NVI1KM7:TR?= MnyzV2FPT0WU
HT M4fvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjZTWM2OD1{LkGwOFU1KM7:TR?= MWXTRW5ITVJ?
RL95-2 M3f3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO2XnpXUUN3ME2yMlEyPDh{IN88US=> Moe2V2FPT0WU
NCI-H1355 Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHyTWM2OD1{LkGxO|kzKM7:TR?= M{X4[XNCVkeHUh?=
NCI-H720 NULvPIk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj3OWNKSzVyPUKuNVY5PzNizszN M1ToXnNCVkeHUh?=
NCI-H1522 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwMkG3NlMh|ryP MmW0V2FPT0WU
LB373-MEL-D M2\hbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz4dlRlUUN3ME2yMlI3QTB{IN88US=> NELqOVBUSU6JRWK=
DG-75 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml73TWM2OD1{LkK3NVQ5KM7:TR?= M1jKT3NCVkeHUh?=
ML-2 NUjNR|N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwM{K4OVUh|ryP MYjTRW5ITVJ?
SF126 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3NbWpmUUN3ME2yMlM{ODl2IN88US=> MVnTRW5ITVJ?
MPP-89 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJwM{OxOFUh|ryP M1HZVHNCVkeHUh?=
NCI-H345 NV60eoJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnWO|BKSzVyPUKuN|MzPzdizszN NITDfm1USU6JRWK=
LS-123 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJwM{S5N|Yh|ryP NG\Je2dUSU6JRWK=
NB10 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nYO2lEPTB;Mj60NVA6OiEQvF2= MmraV2FPT0WU
CGTH-W-1 MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDMSGFZUUN3ME2yMlQzOjZ5IN88US=> MWfTRW5ITVJ?
CP66-MEL NYTwRlE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJwNEe3O{DPxE1? MXnTRW5ITVJ?
L-428 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwNEi1NlEh|ryP M1KzSnNCVkeHUh?=
DMS-79 NXTOWFlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O5TWlEPTB;Mj61OFExOyEQvF2= MnnwV2FPT0WU
NCI-H1882 MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJwNke1OlIh|ryP MVnTRW5ITVJ?
KGN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPCXYFLUUN3ME2yMlc3QDd4IN88US=> NXSzZ4R7W0GQR1XS
EW-1 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqxZ3BPUUN3ME2yMlc4ODh|IN88US=> MYHTRW5ITVJ?
U-266 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2THOWlEPTB;Mj64OFgzOyEQvF2= M{TzRXNCVkeHUh?=
COLO-320-HSR M2nYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL5b2pKSzVyPUKuPFU3PDFizszN M16xOXNCVkeHUh?=
KMOE-2 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnTOYFKSzVyPUKuPFc4OTFizszN NUTQUI1SW0GQR1XS
BB49-HNC MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDRPWFKSzVyPUKuPVI1QCEQvF2= MmeyV2FPT0WU
GI-1 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJwOUK5OVch|ryP NFjnRlJUSU6JRWK=
NCI-H1304 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;jb4tKSzVyPUOuNFA2OTFizszN M4[4XHNCVkeHUh?=
NCI-H2227 NGTLW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDEVZNPUUN3ME2zMlAzODd7IN88US=> MW\TRW5ITVJ?
U-87-MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNwMEO1NVMh|ryP M3myPHNCVkeHUh?=
NCI-H747 NFOzZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT6TFNKSzVyPUOuNFUzODZizszN MU\TRW5ITVJ?
CTB-1 M13K[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3kTWM2OD1|LkC1N|c3KM7:TR?= M1nPNXNCVkeHUh?=
RPMI-8226 NXjRRVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHuUHFKSzVyPUOuNVQ{PzhizszN NUC0XplEW0GQR1XS
NCI-H2141 MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX5TWM2OD1|LkG2OVY3KM7:TR?= NIGzdFlUSU6JRWK=
IST-MES1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTFbIZKSzVyPUOuNVgzPzlizszN MV7TRW5ITVJ?
TE-5 NGTUb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfmWWpkUUN3ME2zMlIyOzR{IN88US=> M1PleHNCVkeHUh?=
UACC-257 NUfZ[VdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrIPIpKSzVyPUOuOFM3PTlizszN NXXTc3RrW0GQR1XS
SK-N-FI NIT2eWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MortTWM2OD1|LkS1NlI4KM7:TR?= M2n5cXNCVkeHUh?=
MFH-ino Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPNUGVKSzVyPUOuOFY2QDlizszN MlXJV2FPT0WU
SF268 NYr3SVlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzaUYloUUN3ME2zMlQ5OTd2IN88US=> M1;YXnNCVkeHUh?=
TE-12 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP6NJVKSzVyPUOuOVE3QTlizszN NUW4TGFZW0GQR1XS
NB6 NUe5[mJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTNwNUW1OlMh|ryP MnvkV2FPT0WU
DJM-1 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\OTWM2OD1|LkW5PFk6KM7:TR?= M1;NTXNCVkeHUh?=
MZ1-PC MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHMTWM2OD1|Lk[xOlI1KM7:TR?= M37lenNCVkeHUh?=
OCI-AML2 M1L3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jSTmlEPTB;Mz62NlY4OSEQvF2= MYrTRW5ITVJ?
NCI-H1155 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn2dXloUUN3ME2zMlcxQTR5IN88US=> M3;3WHNCVkeHUh?=
RKO NULDVI1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoewTWM2OD1|Lke3NVg6KM7:TR?= NUf4dHNkW0GQR1XS
ECC4 NHnp[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3TTWM2OD1|Lkm3NVk2KM7:TR?= NELqOXRUSU6JRWK=
BB65-RCC NYn0VWVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK3bYNKSzVyPUOuPVc2PDdizszN MmTHV2FPT0WU
EB-3 NYnIbIR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNwOUm2N|Mh|ryP M4rzOnNCVkeHUh?=
SHP-77 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3aTWM2OD12LkCwOVI1KM7:TR?= M{HQXXNCVkeHUh?=
NCI-H2196 MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknvTWM2OD12LkC1OlI2KM7:TR?= MVXTRW5ITVJ?
GI-ME-N MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXxeYwzUUN3ME20MlA3Ozl7IN88US=> M1XVdHNCVkeHUh?=
MN-60 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP1TWM2OD12LkGwPFch|ryP MV;TRW5ITVJ?
NCI-H1694 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jjVmlEPTB;ND6xN|QxPSEQvF2= MkHsV2FPT0WU
LU-65 M3LLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;UTYpKSzVyPUSuNVU{OzJizszN MUTTRW5ITVJ?
NCI-H1436 NX\4R3RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK0NI5[UUN3ME20MlE5OzN|IN88US=> NVz2UW9qW0GQR1XS
KINGS-1 M3v5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTRwM{G0N|Ih|ryP M3i2VXNCVkeHUh?=
GT3TKB NX30b4t[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjFTWM2OD12LkOzNlY5KM7:TR?= NIfFXoZUSU6JRWK=
Becker MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7vTWM2OD12LkO3N|EzKM7:TR?= M1nQWXNCVkeHUh?=
HCC1187 NH63ZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHOXJhKSzVyPUSuPFk3PTdizszN NFPqN|FUSU6JRWK=
D-502MG NXLnUpM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\aTWM2OD13LkCwOFE3KM7:TR?= NGjkSplUSU6JRWK=
VA-ES-BJ NXvkUGM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Ty[2lEPTB;NT6xN|c4QCEQvF2= M17yWnNCVkeHUh?=
NB7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLUTWM2OD13LkG0NVEzKM7:TR?= NVnCcVF4W0GQR1XS
SW962 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjneXZiUUN3ME21MlM5QDF2IN88US=> NYDKbYFbW0GQR1XS
no-11 Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTVwN{[zOFMh|ryP NGCzeGVUSU6JRWK=
KNS-81-FD NVXhWVFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13TXWlEPTB;NT65NFY6PCEQvF2= NFXDbXFUSU6JRWK=
COLO-684 NWf3cnNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHPTWM2OD13Lkm5OFk1KM7:TR?= MUTTRW5ITVJ?
D-263MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PsbmlEPTB;Nj6wPFg6PSEQvF2= MVjTRW5ITVJ?
EW-24 NUP0c|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHGcGRKSzVyPU[uNlg2OSEQvF2= MUDTRW5ITVJ?
TE-10 NUDRVYVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETJR3ZKSzVyPU[uOFI3OjNizszN NF;HeGRUSU6JRWK=
EKVX NFHCRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjKTWM2OD14LkS2N|IyKM7:TR?= NHXN[FNUSU6JRWK=
NCI-H1648 M4r3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\hZ2lEPTB;Nj62O|U2PyEQvF2= MWDTRW5ITVJ?
LB771-HNC NXXxXoo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL1c5p1UUN3ME22MlkzOzBzIN88US=> MnjhV2FPT0WU
SK-MEL-1 M1HCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;t[mlEPTB;OD6xN|E3PiEQvF2= NV7wVGliW0GQR1XS
COLO-668 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRThwMke3PFYh|ryP M3XvXXNCVkeHUh?=
EW-12 NHjacoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm1dpFKSzVyPUiuOFA5ODNizszN MVTTRW5ITVJ?
A253 NXO4[lVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MormTWM2OD16Lki0OlYyKM7:TR?= M1L5WXNCVkeHUh?=
NCI-H2126 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7OTWM2OD16Lki5N|E6KM7:TR?= M1nlZ3NCVkeHUh?=
Calu-6 MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDmfYV3UUN3ME24Mlk6ODR{IN88US=> M3rhbnNCVkeHUh?=
NCI-H23 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTlwMUe3OFYh|ryP M2rxNXNCVkeHUh?=
WSU-NHL M{nWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTlwN{e0O|gh|ryP NEj5cWZUSU6JRWK=
MMAC-SF M1i1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofWTWM2OD17Lkm3PVA1KM7:TR?= MmfXV2FPT0WU
SK-LMS-1 NVW1XnJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX5TWM2OD1zMD6yPFM1KM7:TR?= NV\LT3lIW0GQR1XS
GCIY M2jGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFyLkW5NlQh|ryP NV;nfo9ZW0GQR1XS
TE-15 NWqzN3BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnjfmFVUUN3ME2xNU43ODB2IN88US=> MoLHV2FPT0WU
EoL-1-cell MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rDfGlEPTB;MUGuO|Y5OiEQvF2= NUHSZmlEW0GQR1XS
NCI-H2081 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDTTWM2OD1zMT63O|g3KM7:TR?= NV3IO5E{W0GQR1XS
EW-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHUNVQ2UUN3ME2xNk4zPDZ|IN88US=> M3O5fnNCVkeHUh?=
CAS-1 NFLGc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37jVWlEPTB;MUKuN|Y{OSEQvF2= NGTWdHRUSU6JRWK=
C2BBe1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TJUGlEPTB;MUKuOlE{OSEQvF2= NHjqOXVUSU6JRWK=
D-247MG NIrVNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:yZWlEPTB;MUKuO|k2OiEQvF2= NETNNlVUSU6JRWK=
NCI-SNU-5 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jXO2lEPTB;MUKuPFAyOyEQvF2= MoXrV2FPT0WU
LS-1034 Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfiNmFkUUN3ME2xOE4{QTd3IN88US=> MY\TRW5ITVJ?
EW-18 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjBU2dKSzVyPUG0MlQ1QCEQvF2= NVvYUGJnW0GQR1XS
Raji MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml64TWM2OD1zND61NFQ6KM7:TR?= NEDzNolUSU6JRWK=
D-283MED M1;v[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDKPWxKSzVyPUG0MlYzPzFizszN M3rjUnNCVkeHUh?=
MZ2-MEL MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DFTGlEPTB;MUSuPVY6PiEQvF2= NULMVnN5W0GQR1XS
NCI-SNU-16 NVXhO4hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjiTWM2OD1zNT60OlM{KM7:TR?= M3y4fXNCVkeHUh?=
P30-OHK MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHhbo5KSzVyPUG3Mlc5OzFizszN NVXGNGxoW0GQR1XS
RXF393 MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqzVJhKSzVyPUG5MlAyQDZizszN M1X0c3NCVkeHUh?=
NCI-H1395 NIGx[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTtTWM2OD1{MD62O|A{KM7:TR?= M{Dmb3NCVkeHUh?=
U-698-M M2nneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;NeXd7UUN3ME2yNE44ODd3IN88US=> NU\iW|JjW0GQR1XS
NCI-SNU-1 M4LGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK5b4pQUUN3ME2yNE44OjJ|IN88US=> NITuVlFUSU6JRWK=
SW684 NHe0NFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vLSmlEPTB;MkGuNVcyPiEQvF2= Mn\xV2FPT0WU
NCI-H716 NVPvW|BMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nqO2lEPTB;MkGuN|E2PCEQvF2= NEPPcWJUSU6JRWK=
JVM-2 NETlTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom3TWM2OD1{MT60NVM{KM7:TR?= MXjTRW5ITVJ?
NCI-H1581 M2XzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DHd2lEPTB;MkKuOFE1QCEQvF2= MkTaV2FPT0WU
CA46 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;1TWM2OD1|MT62PVM3KM7:TR?= MnfIV2FPT0WU
SNB75 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXeosxUUN3ME2zN{43PTB|IN88US=> M1zYbHNCVkeHUh?=
KNS-42 NU\1OFZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvkNFVKSzVyPUO1Mlk3OjRizszN MXTTRW5ITVJ?
TUR M3HDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfzO3hKSzVyPUO2MlA2OjFizszN NGLp[JdUSU6JRWK=
REH M{\PfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\Zem5KSzVyPUO3MlgzOTFizszN NGOzbFJUSU6JRWK=
EW-22 NVLnOVNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPkbm1KSzVyPUSyMlI5QDVizszN Ml7hV2FPT0WU
NCI-H446 NXHXfm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTR{Lke4OVMh|ryP NHS5RW1USU6JRWK=
ES3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn0ZlJJUUN3ME20N{4yOzN7IN88US=> NX7NToJNW0GQR1XS
EW-11 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTR2LkiyNVgh|ryP NVfzNlBwW0GQR1XS
RH-1 M{DLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml34TWM2OD12Nz61PFEzKM7:TR?= NVvkbIdNW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID